In our study, we created numerous independent AU-15330-resistant prostate cancer lines and identified two classes of resistance mechanisms: one mechanism by which mutations occur in the drug binding site of SMARCA4 and another mechanism by which ABCB1 is overexpressed. This evidence concerns the gene ABCB1 and Familial prostate cancer.